CASI Pharmaceuticals, Inc. (CASIF): Depreciation & Amortization
$1.20M
Year ended 2025-12-31
0.0%
3-year compound annual growth
+14.9%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.20M | -7.7% | 2026-05-15, From 2025-01-01 |
| 2024-12-31 | $1.30M | -48.0% | 2026-05-15, From 2024-01-01 |
| 2023-12-31 | $2.50M | +108.3% | 2026-05-15, From 2023-01-01 |
| 2022-12-31 | $1.20M | +140.0% | 2025-03-31, From 2022-01-01 |
| 2021-12-31 | $500.0K | -16.7% | 2024-03-28, From 2021-01-01 |
| 2020-12-31 | $600.0K | n/a | 2023-04-26, From 2020-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $1.20M | -7.7% |
| Scynexis Inc (SCYX) | 2024-12-31 | $0 | -100.0% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $109.0K | -53.2% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $220.0K | +94.7% |
| Alumis Inc. (ALMS) | 2025-12-31 | $3.50M | +10.9% |
| Celularity Inc (CELU) | 2025-12-31 | $7.29M | -7.9% |
| uniQure N.V. (QURE) | 2025-12-31 | $14.76M | +16.8% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $958.0K | +141.3% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $3.33M | +6.8% |
Compare CASIF, SCYX, SLGL, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗